ROR1 and breast carcinoma: We treated the breast-cancer PDX cells with cirmtuzumab, a humanized mAb specific for a functional epitope of ROR1 that is distinct from the epitope recognized by the anti-ROR1-mAb 4A5, which we used to generate the anti-ROR1 i.p. We found that treatment of the breast-cancer PDX with cirmtuzumab blocked Wnt5a from inducing ROR1 to complex with cortactin (Fig. 1h, i).